Medtronic
This article was originally published in The Gray Sheet
Executive Summary
Gem II VR (Model 7229) single-chamber implantable cardioverter defibrillator is released in the U.S. and internationally following FDA approval July 27 of a premarket approval application supplement, the company reports July 29. The 39 cc, 77 gram device offers full-energy (30 Joules) and high-energy (35 Joules) options for ventricular rate responsive pacing therapy and is 20% smaller than its predecessor, the 48 cc Gem ICD. Competitors include Guidant (39 cc Mini IV single-chamber ICD/pacer), St. Jude (single-chamber, 34 cc Profile MD ICD), and Angeion (47 cc single-chamber Lyra 2020 ICD)
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.